A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT02774200
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.

Study Details

A one-arm exploratory clinical research program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma （mRCC） Patients.It's arm to evaluate the treatment of advanced metastatic renal cell carcinoma in patients with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life score (QoL) and safety.

Key Dates

Start date
May 31, 2016
Status verified
Mar 2016
Primary completion
Dec 31, 2016
Completion
Jun 30, 2017

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: test group
    Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.

Primary Outcome Measure

objective response rate (ORR) [ Time Frame: 8 weeks ]

Central Contacts

Related Studies